Kemppainen, J.; Kangasmäki, A.; Malaspina, S.; Pape, B.; Jalomäki, J.; Kairemo, K.; Kononen, J.; Joensuu, T.
Single Center Experience with a 4-Week 177Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers 2022, 14, 6155.
https://doi.org/10.3390/cancers14246155
AMA Style
Kemppainen J, Kangasmäki A, Malaspina S, Pape B, Jalomäki J, Kairemo K, Kononen J, Joensuu T.
Single Center Experience with a 4-Week 177Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers. 2022; 14(24):6155.
https://doi.org/10.3390/cancers14246155
Chicago/Turabian Style
Kemppainen, Jukka, Aki Kangasmäki, Simona Malaspina, Bernd Pape, Jarno Jalomäki, Kalevi Kairemo, Juha Kononen, and Timo Joensuu.
2022. "Single Center Experience with a 4-Week 177Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer" Cancers 14, no. 24: 6155.
https://doi.org/10.3390/cancers14246155
APA Style
Kemppainen, J., Kangasmäki, A., Malaspina, S., Pape, B., Jalomäki, J., Kairemo, K., Kononen, J., & Joensuu, T.
(2022). Single Center Experience with a 4-Week 177Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers, 14(24), 6155.
https://doi.org/10.3390/cancers14246155